William Blair Comments on Beauty Health FY2024 Earnings

The Beauty Health Company (NASDAQ:SKIN) – Research analysts at William Blair issued their FY2024 EPS estimates for shares of Beauty Health in a report issued on Wednesday, November 13th. William Blair analyst M. Andrew forecasts that the company will earn ($0.29) per share for the year. The consensus estimate for Beauty Health’s current full-year earnings is ($0.25) per share. William Blair also issued estimates for Beauty Health’s FY2025 earnings at ($0.43) EPS.

Other analysts have also recently issued reports about the stock. Canaccord Genuity Group upped their price target on shares of Beauty Health from $1.25 to $1.75 and gave the company a “hold” rating in a report on Wednesday, November 13th. Stifel Nicolaus reduced their price target on shares of Beauty Health from $4.00 to $2.00 and set a “hold” rating on the stock in a research report on Friday, July 26th. Finally, Piper Sandler reiterated an “underweight” rating and set a $1.00 price target (down from $1.50) on shares of Beauty Health in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $2.55.

Beauty Health Stock Performance

NASDAQ:SKIN opened at $1.57 on Monday. Beauty Health has a 1-year low of $0.91 and a 1-year high of $5.17. The stock has a market cap of $194.09 million, a P/E ratio of -3.73 and a beta of 0.90. The company has a debt-to-equity ratio of 9.23, a current ratio of 6.56 and a quick ratio of 5.57. The firm has a 50-day moving average of $1.58 and a two-hundred day moving average of $1.85.

Hedge Funds Weigh In On Beauty Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Beauty Health in the first quarter worth $200,000. Russell Investments Group Ltd. bought a new stake in shares of Beauty Health in the first quarter valued at approximately $279,000. Price T Rowe Associates Inc. MD increased its position in Beauty Health by 8.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 75,281 shares of the company’s stock worth $335,000 after acquiring an additional 5,934 shares during the period. Bayesian Capital Management LP acquired a new position in Beauty Health during the 1st quarter valued at $521,000. Finally, Jacobs Levy Equity Management Inc. bought a new stake in Beauty Health in the 1st quarter valued at $4,297,000. Institutional investors own 93.26% of the company’s stock.

About Beauty Health

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.